Hypothalamic–Pituitary Autoimmunity in Patients Treated with Anti-PD-1 and Anti-PD-L1 Antibodies

Hypothalamic–Pituitary Autoimmunity in Patients Treated with Anti-PD-1 and Anti-PD-L1 Antibodies

Background: Autoimmune hypophysitis is a frequent immune-related adverse event (irAE) in cancer patients treated with immunecheckpoint inhibitors. Studies seeking anti-pituitary (APA) and anti-hypothalamus (AHA) antibodies in patients treated with anti-PD-1 and anti-PD-L1 are scarce. The aim of this...

Full description

Bibliographic Details
Main Authors: Giuseppe Bellastella, Carla Carbone, Lorenzo Scappaticcio, Paolo Cirillo, Teresa Troiani, Floriana Morgillo, Maria Teresa Vietri, Carminia Maria Della Corte, Vincenzo De Falco, Stefania Napolitano, Maria Ida Maiorino, Annamaria De Bellis, Katherine Esposito
Format: Article
Language:English
Published: MDPI AG 2021-08-01
Series:Cancers
Subjects:
APA
anti-pituitary antibodies
AHA
anti-hypothalamus antibodies
pituitary autoimmunity
anti-PD-1
Online Access:https://www.mdpi.com/2072-6694/13/16/4036

Internet

https://www.mdpi.com/2072-6694/13/16/4036

Similar Items